Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product candidate, in combination with Alimta(R) (pemetrexed) and in combination with Taxotere(R) (docetaxel) as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were presented today at the Eighth International Lung Cancer Congress in Wailea, Hawaii.

The first ongoing study is evaluating Xcytrin plus Alimta and has enrolled 27 patients of which 20 are evaluable for response at this time. Patients are receiving 15mg/kg Xcytrin with a standard dose of Alimta and treatment is repeated every 21 days. Seventeen patients (85%) receiving Xcytrin and Alimta have achieved stabilization of their tumors, with 10 of the 17 still on treatment for up to nine cycles. The median survival time and median time to progression have not been reached, with estimated actuarial survival of 69% at 12 months. Patients still on treatment remain under evaluation for tumor response. The most common severe (Grade 3 or higher) side effects were asthenia (10.3%), pneumonia (10.3%), thrombocytopenia (10.3%), and neutropenia (6.9%).

The other ongoing study is evaluating Xcytrin plus Taxotere and has enrolled 24 patients of which 14 are evaluable for response at this time. Patients are given 15mg/kg Xcytrin with a standard dose of Taxotere and treatment is repeated every 21 days. Thirteen patients (87%) receiving Xcytrin and Taxotere have achieved stabilization of their tumors, with four still on treatment. The median survival time is 8.2 months and the median time to progression is 8.7 months. Patients still on treatment remain under evaluation for
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/20/2009)...RNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulle...rly known as DOR BioPharma, Inc., a late-stage bio...rmed a consortium to develop thermostable technolo...accines. Soligenix received a $9.4 million grant f...us Diseases (NIAID), a division of the National In...
(Date:11/19/2009)...wire/ -- In response to an ever-increasing number ...nes, Operation Pangea II, involving 24 countries, ...rganization,s International Medical Products Anti-... dangers of buying medicines online. ,, The wee...rrests and the seizure of thousands of potentially...
(Date:11/19/2009)...9 Alexza Pharmaceuticals...orporate presentation will be webcast live during ...ce on Wednesday, December 2, 2009 at 9:00 a.m. Eas...The New York Palace Hotel in New York and will be ...CEO. ,, To access the live presentation via t...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 1DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 2DIA 8th Annual Electronic Submissions Conference Addresses Current Developments in eCTD around the World 59225 3Gene Data Tool Advances Prospects for Personalized Medicine 59221 1Gene Data Tool Advances Prospects for Personalized Medicine 59221 2Gene Data Tool Advances Prospects for Personalized Medicine 59221 3Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 1Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 2Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 3
(Date:11/20/2009)...nds more severe cases than with seasonal flu , ...dian researchers are reporting that children with ...H1N1 flu than seasonal flu. , "Asthma has been ...ion with pandemic H1N1 influenza, present in 21 pe...Dr. Upton Allen and fellow researchers from the Ho...
(Date:11/20/2009)... Longtime OB/GYN warns against the new bre...eventative Services Task Force. These guidelines m...f human lives. When is it wrong to be safe than so...ntative Services Task Force recommendations, publi...l Medicine, has set off a firestorm in the medical...
(Date:11/20/2009)...FIELD, Mo., Nov. 20 Missouri state...ouri regions will now have the option to choose Me...esday between Missouri Consolidated Health Care Pl...west and South Central Missouri regions include th...ian, Dade, Dallas, Douglas, Greene, Hickory, Howel...
(Date:11/20/2009)...,, LOS ANGELES, Nov. 20 Califor...ican American Families, The Wall/Las Memorias, Lat...Outreach Program, and the Real Medicine Foundation...calling on the company to reconsider harmful and d...to Blue Shield specifically calls for an end to th...
(Date:11/20/2009)...RK, Nov. 20 Today, iconic denim ...announce the launch of a capsule gift giving colle...he holiday season. This collection is inspired by...ospital,s Thanks and Giving® Program, a hol...rages consumers to "give thanks for the healthy ki...
Breaking Medicine News(10 mins):Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 2Health News:New Breast Cancer Recommendation May Cost Lives While Saving Money 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 2Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 3Health News:California Minority Advocacy Groups Send Letter to Blue Shield of California Calling for an End to Discriminatory Practice that Denies Patients in Pain Access to Proper Medication 4Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 2Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 3
...investigating common painkiller drugs after resear...risk of heart attack//. The new data, culled... drugs doubled heart attack risk. The Europe...naproxen, nimesulide and piroxicam recommends use ...
...32 districts are infected with kala azar, the dead...nd government apathy make the disease endemic to t...arch centres in collaboration with the World Healt...ecting the poor people in villages who can't affor...
...kicked off a new center to produce and sell human ... million project, the first ever in Europe,// envi... dedicated to stem cell research. The Roslin Cells... Transfusion Service. Donated eggs and embry...
...S. uncovered the secrets of the deadly Spanish flu...people across the world.// The pandemic took ...son for the severity of the virus was not understo...he 1918 virus and observing their response. ...
... 27 issue of JAMA says that initial research indic...ive patients has little or no effect on CD4 cell c...s in opinion as to when antiretroviral therapy mus...rt-term risk of progression to AIDS, according to ...
...century, tobacco baron James Duke flicked through ...of 430 million, jabbed his finger at a map of Chin...ll cigarettes." One hundred years on, Duke's ...th-taking scale. Three out of every 10 cigar...
Other Medicine News:Health News:Bihar Districts Affected by Black Fever 2Health News:Bihar Districts Affected by Black Fever 3Health News:Spanish flu virus – secrets uncovere 2Health News:HIV RNA Level Seen As Little Value In Predicting Treatment 2Health News:World's 3 out of 10 Cigarettes Smoked in China 2
Gel Dryer - 5 tray with timer (110-115 Volt only)
...Hoefers Easy Breeze can dry as many as 6 standard ... time. , Comes with everything you need: an open...tform, and two Hoefer Gel Frames. No vacuum pump, ...me is largely responsible for the smooth, flat, wr...
...system, 220-240 V, includes Model 583 gel dryer, H...583 gel dryer is a vacuum-based gel dryer with a d...ure control and three preprogrammed cycles. The Hy...sed for pulling vacuum on gel dryers requiring a v...
Double-Up Gel Dryer System (100/120 V)
Medicine Products: